Oxford BioTherapeutics
  • ABOUT
    • OUR TEAM
    • BOARD OF DIRECTORS
    • INVESTORS
    • OFFICES & LABS
  • PIPELINES
    • INTERNAL PROGRAMS
    • PARTNERED PROGRAMS
  • PARTNERSHIPS
  • OUR SCIENCE
    • IO DISCOVERY PLATFORM >
      • IMMUNE CHECKPOINT TARGETS
      • IO ANTIBODY ENGINEERING
    • OGAP DISCOVERY PLATFORM
    • PUBLICATIONS
  • CAREERS
  • NEWS
    • PRESS RELEASES
    • OBT in the News
  • CONTACT

Publications

Abstracts & Publications

Recent Publications

Date
Location
Title
Details
22 Oct 2022
Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2022 Sep 27:CCR-22.
A Novel B7-H6-targeted IgG-like T-cell Engaging Antibody for the Treatment of Gastrointestinal Tumors.
​View here
8-13 April 2022
AACR Annual Meeting 2022, New Orleans, Louisiana
 
Potential novel immuno-oncology mechanism revealed during translational Phase I immuno-blood profiling of experimental ADC medicine OBT076 in a gastric cancer patient.
View here
8 - 13 April 2022
​ AACR Annual Meeting 2022, New Orleans, Louisiana
​OBT076, a clinical stage ADC, displays synergy with Oxaliplatin and Cisplatin in preclinical gastric cancer models. 
View here
3 – 7 June 2022
ASCO Annual Meeting 2022, Chicago
​ Phase 1 study of OBT076, first in class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy and PK/PD results
View here

Selected Past Publications

Date
Location
Title
Details
27-28 April 2020
AACR Annual Meeting 2020, Virtual meeting. 
Identification and validation of a novel immuno-oncology target and selection of a therapeutic antibody candidate with a pharmacologically beneficial activity profile
​View here
09 January 2020
Haematologica 2020; Volume 105(11):2584-2591

 
 Targeting CD205 with the antibody drug
conjugate MEN1309/OBT076 is an active new
therapeutic strategy in lymphoma models
View here
21 June 2019
Mol Cancer Ther 2019;18:1533–43; AACR
​  MEN1309/OBT076, a First-In-Class Antibody–
Drug Conjugate Targeting CD205 in Solid
Tumors
View here
14-18 April 2018
​ AACR Annual Meeting 2018, Chicago, Illinois
Preclinical Development of a Novel Antibody-Drug  Conjugate Targeting “Cold” Tumors
View here
14-18 April 2018
AACR Annual Meeting 2018, Chicago, Illinois
​ Harnessing novel immune escape mechanisms for cancer therapeutics: OXAB1 target validation, proof of concept and preclinical development
View here
1-5 April 2017
AACR Annual Meeting 2017, Washington, D.C., USA ​
Analysis of tumor infiltrating lymphocytes and in vitro exhausted T cell models to identify unique Immuno-Oncology targets

View here
16-20 April 2016
​ AACR Annual Meeting 2016, New Orleans, Louisiana
The use of proteomics to analyse whole tumors and identify unique stroma cell targets for antibody-based therapeutics
View here
18-22 April 2015
​ AACR Annual Meeting 2015, Philadelphia, Pennsylvania
​ The use of proteomics to analyze whole tumors and identify unique immuno-oncology targets for antibody-based therapeutics
View here
5-9 April 2014
​ AACR Annual Meeting 2014, San Diego, CA
Proteomics and Selecting the Right Combination of Target and Toxin for Antibody-Drug-Conjugate (ADC) Development
View here
31 March - 5 April 2012
AACR Annual Meeting 2012, Chicago
​ Proteomics highlights which G-protein coupled receptors are candidates for ADC development
View here

Privacy Policy

Legal Notice

Site Map

© 2017 Oxford BioTherapeutics All Rights Reserved
  • ABOUT
    • OUR TEAM
    • BOARD OF DIRECTORS
    • INVESTORS
    • OFFICES & LABS
  • PIPELINES
    • INTERNAL PROGRAMS
    • PARTNERED PROGRAMS
  • PARTNERSHIPS
  • OUR SCIENCE
    • IO DISCOVERY PLATFORM >
      • IMMUNE CHECKPOINT TARGETS
      • IO ANTIBODY ENGINEERING
    • OGAP DISCOVERY PLATFORM
    • PUBLICATIONS
  • CAREERS
  • NEWS
    • PRESS RELEASES
    • OBT in the News
  • CONTACT